Related Experiment Videos
Respiratory distress syndrome and inositol supplementation in preterm infants
Insights
Myo-inositol supplementation in preterm infants reduced the need for mechanical ventilation and decreased complications like bronchopulmonary dysplasia. This study suggests inositol is a vital nutrient for premature babies.
Area of Science:
- Neonatal Medicine
- Nutritional Science
- Pediatric Respiratory Medicine
Background:
- Preterm infants, especially those with respiratory distress syndrome, have unique nutritional needs.
- Immature physiological systems in preterm infants increase susceptibility to complications.
- Artificial ventilation is often required for respiratory support in very low birth weight infants.
Purpose of the Study:
- To evaluate the efficacy of myo-inositol supplementation in reducing respiratory complications and improving outcomes in preterm infants.
- To determine if inositol supplementation impacts the need for mechanical ventilation and the incidence of bronchopulmonary dysplasia.
- To assess the safety and tolerability of myo-inositol in this vulnerable population.
Main Methods:
- A randomized, double-blind, placebo-controlled trial was conducted.
- 74 preterm infants (birth weight < 2000 g) requiring artificial ventilation were enrolled.
- Inositol (120-160 mg/kg/day) was administered for 10 days via gastric or intravenous routes.
Main Results:
- Infants receiving inositol required less mechanical ventilation between days 4-10.
- Inositol supplementation was associated with fewer failures of indomethacin to close the ductus arteriosus.
- A significant reduction in deaths or bronchopulmonary dysplasia was observed in the inositol group compared to placebo.
Conclusions:
- Myo-inositol supplementation appears to be beneficial for immature preterm infants.
- Inositol may play a crucial role in the nutritional support of very low birth weight infants.
- Further research is warranted to confirm these preliminary findings and elucidate the mechanisms of action.
Abstract:
We report a randomised double blind trial of myo-inositol (inositol) supplementation for 10 days in 74 preterm infants with a birth weight less than 2000 g (mean gestational age 29.5 weeks and mean birth weight 1266 g). All infants required artificial ventilation for treatment of respiratory distress syndrome. Inositol (120-160 mg/kg/day) was administered by the ingastric or intravenous route. The 37 infants who received inositol supplementation required less mechanical ventilation during days 4-10, had less failures of indomethacin to close ductus arteriosus, and had less deaths or bronchopulmonary dysplasia, or both, than the infants treated with placebo. There were no detectable adverse effects. These preliminary results suggest that inositol is an important nutrient in immature preterm infants.